Fluidigm Corporation  

(Public, NASDAQ:FLDM)   Watch this stock  
Find more results for Gene Smith´┐Ż
19.95
-0.08 (-0.40%)
After Hours: 19.95 0.00 (0.00%)
Aug 3, 5:40PM EDT  
NASDAQ real-time data - Disclaimer
Currency in USD
Range 19.46 - 20.61
52 week 19.10 - 46.38
Open 20.08
Vol / Avg. 239,444.00/259,684.00
Mkt cap 578.13M
P/E     -
Div/yield     -
EPS -1.89
Shares 28.86M
Beta 0.98
Inst. own 108%
Aug 6, 2015
Q2 2015 Fluidigm Corp Earnings Call - 5:00PM EDT - Add to calendar
Aug 6, 2015
Q2 2015 Fluidigm Corp Earnings Release - 4:00PM EDT - Add to calendar
Jul 29, 2015
Fluidigm Corp Annual Shareholders Meeting
May 7, 2015
Q1 2015 Fluidigm Corp Earnings Call - Webcast
May 7, 2015
Q1 2015 Fluidigm Corp Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -59.60% -45.36%
Operating margin -52.38% -44.51%
EBITD margin - -26.91%
Return on average assets -15.92% -20.15%
Return on average equity -43.64% -42.81%
Employees 474 -
CDP Score - -

Address

7000 Shoreline Ct Ste 100
SOUTH SAN FRANCISCO, CA 94080-7603
United States - Map
+1-650-2666000 (Phone)
+1-650-8717152 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Fluidigm Corporation creates, manufactures and market technologies and life science tools focused on the exploration and analysis of single cells, as well as the industrial application of genomics, based upon the Company’s core microfluidics and mass cytometry technologies. The Company also offers instruments and consumables to academic institutions, clinical laboratories, pharmaceutical, biotechnology and agricultural biotechnology (Ag-Bio) companies. The Company sells technologies and life-science tools, including analytical and preparatory systems for genomic and proteomic analysis, and consumables, including Integrated Fluidic Circuits (IFCs), assays, and reagents. The Company’s products include C1 Single-Cell Auto Prep System; Access Array System; Biomark HD System; EP1 System; CyTOF 2 System; IFCs include C1 IFCs; Access Array IFC; Dynamic Array IFCs; Digital Array IFCs; Flex Six IFC; Access Array Target-Specific Primers, and Maxpar Reagents, among others.

Officers and directors

Samuel D. Colella MBA Independent Chairman of the Board
Age: 75
Bio & Compensation  - Reuters
Gajus Vincent Worthington President, Chief Executive Officer, Director
Age: 45
Bio & Compensation  - Reuters
Vikram Jog Chief Financial Officer
Age: 59
Bio & Compensation  - Reuters
Fredric T. Walder Chief Operating Officer
Age: 57
Bio & Compensation  - Reuters
William Maxwell Smith J.D. Executive Vice President - Legal Affairs, General Counsel, Secretary
Age: 64
Bio & Compensation  - Reuters
Robert C. Jones Executive Vice President - Research and Development
Age: 60
Bio & Compensation  - Reuters
Mai Chan Yow Executive Vice President - Worldwide Manufacturing and Managing Director
Age: 56
Bio & Compensation  - Reuters
Gerhard F. Burbach Independent Director
Age: 53
Bio & Compensation  - Reuters
Evan Jones Independent Director
Age: 58
Bio & Compensation  - Reuters
Patrick Schwager Jones Independent Director
Age: 70
Bio & Compensation  - Reuters